nach oben

Endocrine

Erschienen in:

01.10.2019 | Review

Thyroid hormone therapy in differentiated thyroid cancer

verfasst von: Giorgio Grani, Valeria Ramundo, Antonella Verrienti, Marialuisa Sponziello, Cosimo Durante

Erschienen in: Endocrine | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Surgery—with or without postoperative radioiodine—is the standard of care for most patients with differentiated thyroid carcinoma (DTC). Thyroid hormone replacement therapy is the mainstay of long-term medical management. Patients treated with total thyroidectomy and some who undergo lobectomy alone require thyroid hormone therapy to restore euthyroidism with normal serum thyroid-stimulating hormone (TSH) levels. Because TSH acts as a growth factor for thyroid follicular cells (including those that are neoplastic), it can potentially affect the onset and/or progression of follicular-cell derived thyroid cancer. For this reason, some patients are placed on thyroid hormone therapy at doses that suppress secretion of TSH (suppression therapy). This mini-review looks at the potential benefits and risks of this practice in patients diagnosed with DTC. Aggressive TSH-suppressive therapy is of little or no benefit to the vast majority of patients with DTC. Practice guidelines, therefore, recommend a graded algorithm in which the potential benefits of suppression are weighed against the associated cardiovascular and skeletal risks. Large randomized controlled studies are needed to confirm the presumed oncological benefits of TSH-suppression and its causal role in adverse cardiac, skeletal, and quality of life effects and to assess the efficacy of TSH normalization in reversing or reducing these effects.

L. Lamartina, C. Durante, G. Lucisano, G. Grani, R. Bellantone, C.P. Lombardi, A. Pontecorvi, E. Arvat, F. Felicetti, M.C. Zatelli, R. Rossi, E. Puxeddu, S. Morelli, M. Torlontano, U. Crocetti, T. Montesano, R. Giubbini, F. Orlandi, G. Aimaretti, F. Monzani, M. Attard, C. Francese, A. Antonelli, P. Limone, R. Rossetto, L. Fugazzola, D. Meringolo, R. Bruno, S. Tumino, G. Ceresini, M. Centanni, S. Monti, D. Salvatore, G. Spiazzi, C. Mian, L. Persani, D. Barbaro, A. Nicolucci, S. Filetti, Are evidence-based guidelines reflected in clinical practice? An analysis of prospectively collected data of the Italian Thyroid Cancer Observatory. Thyroid 27(12), 1490–1497 (2017). https://doi.org/10.1089/thy.2017.0299 CrossRefPubMed

M.C. Zatelli, L. Lamartina, D. Meringolo, E. Arvat, L. Damiani, G. Grani, A. Nervo, C. Durante, L. Giacomelli, Thyroid nodule recurrence following lobo-isthmectomy: incidence, patient’s characteristics, and risk factors. J. Endocrinol. Invest 41(12), 1469–1475 (2018). https://doi.org/10.1007/s40618-018-0946-5 CrossRefPubMed

R. Bruno, E. Ferretti, E. Tosi, F. Arturi, P. Giannasio, T. Mattei, A. Scipioni, I. Presta, R. Morisi, A. Gulino, S. Filetti, D. Russo, Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J. Clin. Endocrinol. Metab. 90(10), 5692–5697 (2005). https://doi.org/10.1210/jc.2005-0800 CrossRefPubMed

R.R. Cavalieri, Iodine metabolism and thyroid physiology: current concepts. Thyroid 7(2), 177–181 (1997). https://doi.org/10.1089/thy.1997.7.177 CrossRefPubMed

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016). https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral

M. Luster, C. Aktolun, I. Amendoeira, M. Barczynski, K.C. Bible, L.H. Duntas, R. Elisei, D. Handkiewicz-Junak, M. Hoffmann, B. Jarzab, L. Leenhardt, T.J. Musholt, K. Newbold, I.J. Nixon, J. Smit, M. Sobrinho-Simoes, J.A. Sosa, R.M. Tuttle, F.A. Verburg, L. Wartofsky, D. Fuhrer, European perspective on 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: proceedings of an interactive international symposium. Thyroid 29(1), 7–26 (2019). https://doi.org/10.1089/thy.2017.0129 CrossRefPubMed

B. Biondi, S. Filetti, M. Schlumberger, Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat. Clin. Pr. Endocrinol. Metab. 1(1), 32–40 (2005). https://doi.org/10.1038/ncpendmet0020 CrossRef

B. Biondi, D.S. Cooper, Thyroid hormone suppression therapy. Endocrinol. Metab. Clin. North Am. 48(1), 227–237 (2019). https://doi.org/10.1016/j.ecl.2018.10.008 CrossRefPubMed

S. Filetti, J.M. Bidart, F. Arturi, B. Caillou, D. Russo, M. Schlumberger, Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur. J. Endocrinol. 141(5), 443–457 (1999)CrossRef

10.

C. Durante, E. Puxeddu, E. Ferretti, R. Morisi, S. Moretti, R. Bruno, F. Barbi, N. Avenia, A. Scipioni, A. Verrienti, E. Tosi, A. Cavaliere, A. Gulino, S. Filetti, D. Russo, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92(7), 2840–2843 (2007). https://doi.org/10.1210/jc.2006-2707 CrossRefPubMed

11.

M. D’Agostino, M. Sponziello, C. Puppin, M. Celano, V. Maggisano, F. Baldan, M. Biffoni, S. Bulotta, C. Durante, S. Filetti, G. Damante, D. Russo, Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J. Mol. Endocrinol. 52(2), 121–131 (2014). https://doi.org/10.1530/jme-13-0160 CrossRefPubMed

12.

M.R. Haymart, D.J. Repplinger, G.E. Leverson, D.F. Elson, R.S. Sippel, J.C. Jaume, H. Chen, Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J. Clin. Endocrinol. Metab. 93(3), 809–814 (2008). https://doi.org/10.1210/jc.2007-2215 CrossRefPubMed

13.

H.K. Kim, J.H. Yoon, S.J. Kim, J.S. Cho, S.S. Kweon, H.C. Kang, Higher TSH level is a risk factor for differentiated thyroid cancer. Clin. Endocrinol. (Oxf.) 78(3), 472–477 (2013). https://doi.org/10.1111/cen.12027 CrossRef

14.

L. Golbert, A.P. de Cristo, C.S. Faccin, M. Farenzena, H. Folgierini, M.S. Graudenz, A.L. Maia, T.S.H. Serum, levels as a predictor of malignancy in thyroid nodules: A prospective study. PLoS One 12(11), e0188123 (2017). https://doi.org/10.1371/journal.pone.0188123 CrossRefPubMedPubMedCentral

15.

A.A. Tam, D. Ozdemir, C. Aydin, N. Bestepe, S. Ulusoy, N. Sungu, R. Ersoy, B. Cakir, Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer. Endocrine 59(3), 565–572 (2018). https://doi.org/10.1007/s12020-018-1523-6 CrossRefPubMed

16.

I. Sugitani, Y. Fujimoto, Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J. Clin. Endocrinol. Metab. 95(10), 4576–4583 (2010). https://doi.org/10.1210/jc.2010-0161 CrossRefPubMed

17.

J. Jonklaas, N.J. Sarlis, D. Litofsky, K.B. Ain, S.T. Bigos, J.D. Brierley, D.S. Cooper, B.R. Haugen, P.W. Ladenson, J. Magner, J. Robbins, D.S. Ross, M. Skarulis, H.R. Maxon, S.I. Sherman, Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16(12), 1229–1242 (2006). https://doi.org/10.1089/thy.2006.16.1229 CrossRefPubMed

18.

E.L. Mazzaferri, S.M. Jhiang, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97(5), 418–428 (1994)CrossRef

19.

N.J. McGriff, G. Csako, L. Gourgiotis, C.G. Lori, F. Pucino, N.J. Sarlis, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann. Med 34(7-8), 554–564 (2002)CrossRef

20.

D.S. Cooper, B. Specker, M. Ho, M. Sperling, P.W. Ladenson, D.S. Ross, K.B. Ain, S.T. Bigos, J.D. Brierley, B.R. Haugen, I. Klein, J. Robbins, S.I. Sherman, T. Taylor, H.R. Maxon 3rd, : Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8(9), 737–744 (1998). https://doi.org/10.1089/thy.1998.8.737 CrossRefPubMed

21.

S. Diessl, B. Holzberger, U. Mader, I. Grelle, J.W. Smit, A.K. Buck, C. Reiners, F.A. Verburg, Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 76(4), 586–592 (2012). https://doi.org/10.1111/j.1365-2265.2011.04272.x CrossRef

22.

Y. Ito, H. Masuoka, M. Fukushima, H. Inoue, M. Kihara, C. Tomoda, T. Higashiyama, Y. Takamura, K. Kobayashi, A. Miya, A. Miyauchi, Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan. Endocr. J. 57(6), 523–531 (2010)CrossRef

23.

J. Klubo-Gwiezdzinska, S. Auh, M. Gershengorn, B. Daley, A. Bikas, K. Burman, L. Wartofsky, M. Urken, E. Dewey, R. Smallridge, A.M. Chindris, E. Kebebew, Association of thyrotropin suppression with survival outcomes in patients with intermediate- and high-risk differentiated thyroid cancer. JAMA Netw. Open 2(2), e187754 (2019). https://doi.org/10.1001/jamanetworkopen.2018.7754 CrossRefPubMedPubMedCentral

24.

G.C. Hovens, M.P. Stokkel, J. Kievit, E.P. Corssmit, A.M. Pereira, J.A. Romijn, J.W. Smit, Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 92(7), 2610–2615 (2007). https://doi.org/10.1210/jc.2006-2566 CrossRefPubMed

25.

B. Biondi, D.S. Cooper, Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 20(2), 135–146 (2010). https://doi.org/10.1089/thy.2009.0311 CrossRefPubMed

26.

Q. Xia, S. Dong, P.D. Bian, J. Wang, C.J. Li, Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma. Eur. Arch. Otorhinolaryngol. 273(4), 1037–1043 (2016). https://doi.org/10.1007/s00405-015-3564-2 CrossRefPubMed

27.

L.Y. Wang, A.W. Smith, F.L. Palmer, R.M. Tuttle, A. Mahrous, I.J. Nixon, S.G. Patel, I. Ganly, J.A. Fagin, L. Boucai, Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid 25(3), 300–307 (2015). https://doi.org/10.1089/thy.2014.0287 CrossRefPubMed

28.

P. Perros, K. Boelaert, S. Colley, C. Evans, R.M. Evans, G. Gerrard Ba, J. Gilbert, B. Harrison, S.J. Johnson, T.E. Giles, L. Moss, V. Lewington, K. Newbold, J. Taylor, R.V. Thakker, J. Watkinson, G.R. Williams, Guidelines for the management of thyroid cancer. Clin. Endocrinol. (Oxf.) 81(Suppl 1), 1–122 (2014). https://doi.org/10.1111/cen.12515 CrossRef

29.

L. Lamartina, T. Montesano, R. Falcone, M. Biffoni, G. Grani, M. Maranghi, L. Ciotti, L. Giacomelli, V. Ramundo, C. Lomonaco, C.R. Di Gioia, P. Lucia, G. Ronga, C. Durante, Is it worth suppressing tsh in low- and intermediate-risk papillary thyroid cancer patients before the first disease assessment? Endocr. Pract. 25(2), 165–169 (2019). https://doi.org/10.4158/EP-2018-0393 CrossRefPubMed

30.

T. Tian, R. Huang, B. Liu, Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment? Endocrine (2019). https://doi.org/10.1007/s12020-019-01914-z

31.

M.C. Lee, M.J. Kim, H.S. Choi, S.W. Cho, G.H. Lee, Y.J. Park, D.J. Park, Postoperative thyroid-stimulating hormone levels did not affect recurrence after thyroid lobectomy in patients with papillary thyroid cancer. Endocrinol Metab (Seoul) 34(2), 150–157 (2019). https://doi.org/10.3803/EnM.2019.34.2.150 CrossRef

32.

S. Park, W.G. Kim, M. Han, M.J. Jeon, H. Kwon, M. Kim, T.Y. Sung, T.Y. Kim, W.B. Kim, S.J. Hong, Y.K. Shong, Thyrotropin suppressive therapy for low-risk small thyroid cancer: a propensity score-matched cohort study. Thyroid 27(9), 1164–1170 (2017). https://doi.org/10.1089/thy.2017.0177 CrossRefPubMed

33.

G. Grani, L. Lamartina, C. Durante, S. Filetti, D.S. Cooper, Follicular thyroid cancer and Hurthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes &. Endocrinology 6(6), 500–514 (2018). https://doi.org/10.1016/S2213-8587(17)30325-X CrossRef

34.

Y.M. Lee, Y.H. Lee, D.E. Song, W.B. Kim, T.Y. Sung, J.H. Yoon, K.W. Chung, S.J. Hong, Prognostic impact of further treatments on distant metastasis in patients with minimally invasive follicular thyroid carcinoma: verification using inverse probability of treatment weighting. World J. Surg. 41(1), 138–145 (2017). https://doi.org/10.1007/s00268-016-3608-9 CrossRefPubMed

35.

R. Petric, B. Gazic, N. Besic, Prognostic factors for disease-specific survival in 108 patients with Hurthle cell thyroid carcinoma: a single-institution experience. BMC cancer 14, 777 (2014). https://doi.org/10.1186/1471-2407-14-777 CrossRefPubMedPubMedCentral

36.

T.G. de Melo, D.E. Zantut-Wittmann, E. Ficher, L.V. da Assumpcao, Factors related to mortality in patients with papillary and follicular thyroid cancer in long-term follow-up. J. Endocrinol. Invest 37(12), 1195–1200 (2014). https://doi.org/10.1007/s40618-014-0131-4 CrossRefPubMed

37.

A. Pisanu, D. Deplano, M. Pili, A. Uccheddu, Larger tumor size predicts nodal involvement in patients with follicular thyroid carcinoma. Tumori 97(3), 296–303 (2011). https://doi.org/10.1700/912.10025 CrossRefPubMed

38.

F.A. Verburg, M.P. Stokkel, C. Duren, R.B. Verkooijen, U. Mader, J.W. van Isselt, R.J. Marlowe, J.W. Smit, C. Reiners, M. Luster, No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. imaging 37(2), 276–283 (2010). https://doi.org/10.1007/s00259-009-1315-6 CrossRefPubMed

39.

M.A. Gulcelik, N.E. Gulcelik, B. Kuru, M. Camlibel, H. Alagol, Prognostic factors determining survival in differentiated thyroid cancer. J. Surg. Oncol. 96(7), 598–604 (2007). https://doi.org/10.1002/jso.20845 CrossRefPubMed

40.

M. Haq, C. Harmer, Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin. Endocrinol. (Oxf.) 63(1), 87–93 (2005). https://doi.org/10.1111/j.1365-2265.2005.02304.x CrossRef

41.

Y. Ito, A. Miyauchi, H. Inoue, M. Fukushima, M. Kihara, T. Higashiyama, C. Tomoda, Y. Takamura, K. Kobayashi, A. Miya, An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J. Surg. 34(1), 28–35 (2010). https://doi.org/10.1007/s00268-009-0303-0 CrossRefPubMed

42.

Y. Ito, T. Uruno, K. Nakano, Y. Takamura, A. Miya, K. Kobayashi, T. Yokozawa, F. Matsuzuka, S. Kuma, K. Kuma, A. Miyauchi, An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13(4), 381–387 (2003). https://doi.org/10.1089/105072503321669875 CrossRefPubMed

43.

R.M. Tuttle, J.A. Fagin, G. Minkowitz, R.J. Wong, B. Roman, S. Patel, B. Untch, I. Ganly, A.R. Shaha, J.P. Shah, M. Pace, D. Li, A. Bach, O. Lin, A. Whiting, R. Ghossein, I. Landa, M. Sabra, L. Boucai, S. Fish, L.G.T. Morris, Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol. Head. Neck Surg. 143(10), 1015–1020 (2017). https://doi.org/10.1001/jamaoto.2017.1442 CrossRefPubMedPubMedCentral

44.

H.I. Kim, H.W. Jang, H.S. Ahn, S. Ahn, S.Y. Park, Y.L. Oh, S.Y. Hahn, J.H. Shin, J.H. Kim, J.S. Kim, J.H. Chung, T.H. Kim, S.W. Kim, High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance. J. Clin. Endocrinol. Metab. 103(2), 446–451 (2018). https://doi.org/10.1210/jc.2017-01775 CrossRefPubMed

45.

I. Sugitani, Y. Fujimoto, K. Yamada, Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J. Surg. 38(3), 673–678 (2014). https://doi.org/10.1007/s00268-013-2335-8 CrossRefPubMed

46.

C. Do Cao, J.L. Wemeau, Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer. Ann. Endocrinol. (Paris) 76(1 Suppl 1), 1s47–52s47 (2015). https://doi.org/10.1016/s0003-4266(16)30014-2 CrossRef

47.

B. Biondi, S. Fazio, A. Cuocolo, D. Sabatini, E. Nicolai, G. Lombardi, M. Salvatore, L. Sacca, Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 81(12), 4224–4228 (1996). https://doi.org/10.1210/jcem.81.12.8954019 CrossRefPubMed

48.

N. Pajamaki, S. Metso, T. Hakala, T. Ebeling, H. Huhtala, E. Ryodi, J. Sand, A. Jukkola-Vuorinen, P.L. Kellokumpu-Lehtinen, P. Jaatinen, Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clin. Endocrinol. (Oxf.) 88(2), 303–310 (2018). https://doi.org/10.1111/cen.13519 CrossRef

49.

J. Park, B.E. Blackburn, P.A. Ganz, K. Rowe, J. Snyder, Y. Wan, V. Deshmukh, M. Newman, A. Fraser, K. Smith, K. Herget, A.C. Kirchhoff, D. Abraham, J. Kim, M. Monroe, M. Hashibe, Risk factors for cardiovascular disease among thyroid cancer survivors: findings from the Utah Cancer Survivors Study. J. Clin. Endocrinol. Metab. 103(7), 2468–2477 (2018). https://doi.org/10.1210/jc.2017-02629 CrossRefPubMed

50.

E.H. Kim, Y.K. Jeon, K. Pak, I.J. Kim, S.J. Kim, S. Shin, B.H. Kim, S.S. Kim, B.J. Lee, J.G. Lee, T.S. Goh, K. Kim, Effects of thyrotropin suppression on bone health in menopausal women with total thyroidectomy. J. Bone Metab. 26(1), 31–38 (2019). https://doi.org/10.11005/jbm.2019.26.1.31 CrossRefPubMedPubMedCentral

51.

M.L. Quan, J.L. Pasieka, O. Rorstad, Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J. Surg. Oncol. 79(1), 62–69 (2002). discussion 69-70CrossRef

52.

K.A. Heemstra, N.A. Hamdy, J.A. Romijn, J.W. Smit, The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 16(6), 583–591 (2006). https://doi.org/10.1089/thy.2006.16.583 CrossRefPubMed

53.

B. Biondi, D.S. Cooper, Subclinical hyperthyroidism. N. Engl. J. Med 379(15), 1485–1486 (2018). https://doi.org/10.1056/NEJMc1809627 CrossRefPubMed

54.

B.H. Yoon, Y. Lee, H.J. Oh, S.H. Kim, Y.K. Lee, Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: a meta-analysis. J. Bone Metab. 26(1), 51–60 (2019). https://doi.org/10.11005/jbm.2019.26.1.51 CrossRefPubMedPubMedCentral

55.

S. Tagay, S. Herpertz, M. Langkafel, Y. Erim, L. Freudenberg, N. Schopper, A. Bockisch, W. Senf, R. Gorges, Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur. J. Endocrinol. 153(6), 755–763 (2005). https://doi.org/10.1530/eje.1.02047 CrossRefPubMed

56.

G. Grani, D. Tumino, V. Ramundo, L. Ciotti,C. Lomonaco, M. Armillotta, R. Falcone, P. Lucia, M. Maranghi, S. Filetti, C. Durante, Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments. J Endocrinol Invest (2019). https://doi.org/10.1007/s40618-019-01074-x

Titel: Thyroid hormone therapy in differentiated thyroid cancer
verfasst von: Giorgio Grani
Valeria Ramundo
Antonella Verrienti
Marialuisa Sponziello
Cosimo Durante
Publikationsdatum: 01.10.2019
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02051-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

T4 + T3 combination therapy: any progress?

Thyroid hormone misuse and abuse

Thyroid hormone metabolites and analogues

Thyroid hormone therapy of hypothyroidism in pregnancy

Thyroid hormone therapy: past, present, and future